SCHEMBL3344092

SCHEMBL3344092

NC(Cc1ccc(-c2noc(-c3cn4cc(C(F)(F)F)cc(Cl)c4n3)n2)c(Cl)c1)=NO

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.43
NFKB1 P19838 4/20 0.43
RAB9A P51151 4/20 0.43
NFKB2 Q00653 4/20 0.43
RELA Q04206 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
MAPT P10636 2/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C19 P33261 2/20 0.42
LMNA P02545 1/20 0.42
CYP2C9 P11712 1/20 0.42
RECQL P46063 1/20 0.42
PKM P14618 1/20 0.42
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HDAC6 Q9UBN7 3/20 0.37
HDAC4 P56524 2/20 0.37
HDAC3 O15379 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3344091 1.00 NPC1 (0.43) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL2477214 0.87 SMN1; SMN2 (0.47) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3338625 0.86 NPC1 (0.48) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3343600 0.86 NPC1 (0.46) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3343603 0.86 NPC1 (0.46) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3342630 0.85 NPC1 (0.47) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL13326583 0.85 SMN1; SMN2 (0.47) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3340118 0.85 NPC1 (0.48) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3339708 0.84 NPC1 (0.43) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3339549 0.84 SMN1; SMN2 (0.46) NPC1NFKB1RAB9ANFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 NPC1 241/4885NFKB1 3452/4885RAB9A 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.